{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:53:05Z","timestamp":1791244385034,"version":"4.1.0"},"reference-count":13,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015338","name":"Cancer Moonshot","doi-asserted-by":"publisher","award":["U54CA224068"],"award-info":[{"award-number":["U54CA224068"]}],"id":[{"id":"10.13039\/100015338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The tumor-suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1\/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including (i) DNA-binding domain mutations or frameshift\/nonsense mutations that abolish transcriptional activity and (ii) mutations within the Y220C-binding surface predicted to hinder drug binding. Functional modeling confirmed that these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study illustrates how pan-cancer resistance to Y220C-mutant p53 reactivators emerges in patients, indicating that on-target acquired alterations can represent a major mechanism of clinical resistance. These insights establish a molecular basis for therapeutic failure and provide a framework for developing next-generation agents to overcome resistance.<\/jats:p>\n                    <jats:p>See related commentary by Liu and Gu, p. 620<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-25-1761","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:01:52Z","timestamp":1767884512000},"page":"677-685","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-4838","authenticated-orcid":false,"given":"Ferran","family":"Fece de la Cruz","sequence":"first","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5776-8844","authenticated-orcid":false,"given":"Andreas","family":"Varkaris","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0326-7902","authenticated-orcid":false,"given":"Parasvi S.","family":"Patel","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3533-9856","authenticated-orcid":false,"given":"Elijah W.","family":"Kushner","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0534-2634","authenticated-orcid":false,"given":"Alvin A.","family":"Morales-Giron","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-4269","authenticated-orcid":false,"given":"Sangmi Sandra","family":"Lee","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."},{"name":"2Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6522-9223","authenticated-orcid":false,"given":"Ankit","family":"Singh","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0655-274X","authenticated-orcid":false,"given":"Clara T.","family":"Kim","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-473X","authenticated-orcid":false,"given":"Bryanna L.","family":"Norden","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-0789","authenticated-orcid":false,"given":"Sara","family":"Ehnstrom","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-4715","authenticated-orcid":false,"given":"Jakob M.","family":"Riedl","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."},{"name":"4Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7828-9272","authenticated-orcid":false,"given":"Jacquelyn M.","family":"Curtis","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2190-8969","authenticated-orcid":false,"given":"Haley","family":"Barnes","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0246-4023","authenticated-orcid":false,"given":"Allison M.","family":"Kehlmann","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0116-8108","authenticated-orcid":false,"given":"Nicholas J.","family":"Chevalier","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-7361","authenticated-orcid":false,"given":"Hitomi S.","family":"Okuma","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."},{"name":"5Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4272-4353","authenticated-orcid":false,"given":"Manisha","family":"Patel","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-2289","authenticated-orcid":false,"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-5903","authenticated-orcid":false,"given":"Brendan","family":"Connell","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03mbq3y29","id-type":"ROR","asserted-by":"publisher"}],"name":"Lahey Hospital and Medical Center 6 Department of Hematology-Oncology, , Burlington, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3515-6905","authenticated-orcid":false,"given":"Francis","family":"Nugent","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03mbq3y29","id-type":"ROR","asserted-by":"publisher"}],"name":"Lahey Hospital and Medical Center 7 , Tufts University School of Medicine, Burlington, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0589-8265","authenticated-orcid":false,"given":"Leontios","family":"Pappas","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3894-3610","authenticated-orcid":false,"given":"Kayao","family":"Lau","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-7704","authenticated-orcid":false,"given":"Dejan","family":"Juric","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1562-445X","authenticated-orcid":false,"given":"Jessica L.","family":"Hopkins","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8149-4262","authenticated-orcid":false,"given":"Keelan Z.","family":"Guiley","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043mz5j54","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California 8 Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, , San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-7741","authenticated-orcid":false,"given":"Kevan M.","family":"Shokat","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043mz5j54","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California 8 Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, , San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5419-0549","authenticated-orcid":false,"given":"Doga C.","family":"Gulhan","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."},{"name":"2Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-7841","authenticated-orcid":false,"given":"Aparna R.","family":"Parikh","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8173-5778","authenticated-orcid":false,"given":"Ryan B.","family":"Corcoran","sequence":"additional","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026040103144281700_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41571-023-00842-2","article-title":"Pharmacological reactivation of p53 in the era of precision anticancer medicine","volume":"21","author":"Tuval","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026040103144281700_bib2","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1073\/pnas.0607286103","article-title":"Structural basis for understanding oncogenic p53 mutations and designing rescue drugs","volume":"103","author":"Joerger","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026040103144281700_bib3","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.4155\/fmc-2019-0181","article-title":"A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C","volume":"11","author":"Bauer","year":"2019","journal-title":"Future Med Chem"},{"key":"2026040103144281700_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsmedchemlett.4c00379","article-title":"Discovery of rezatapopt (PC14586), a first-in-class, small-molecule reactivator of p53 Y220C mutant in development","volume":"16","author":"Vu","year":"2025","journal-title":"ACS Med Chem Lett"},{"key":"2026040103144281700_bib5","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1080\/14796694.2025.2557176","article-title":"PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation","volume":"21","author":"Schram","year":"2025","journal-title":"Future Oncol"},{"issue":"Suppl 16","key":"2026040103144281700_bib6","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2022.40.16_suppl.3003","article-title":"First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation","volume":"40","author":"Dumbrava","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026040103144281700_bib7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/2159-8290.CD-24-1421","article-title":"Restoration of the tumor suppressor function of Y220C-mutant p53 by rezatapopt, a small molecule reactivator","volume":"15","author":"Puzio-Kuter","year":"2025","journal-title":"Cancer Discov"},{"key":"2026040103144281700_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2159-8290.CD-22-0381","article-title":"A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability","volume":"13","author":"Guiley","year":"2023","journal-title":"Cancer Discov"},{"key":"2026040103144281700_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026040103144281700_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death Differ"},{"key":"2026040103144281700_bib11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","article-title":"Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations","volume":"5","author":"Ahronian","year":"2015","journal-title":"Cancer Discov"},{"key":"2026040103144281700_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2026040103144281700_bib13","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1093\/nar\/gkw227","article-title":"VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research","volume":"44","author":"Lai","year":"2016","journal-title":"Nucleic Acids Res"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1761\/3723751\/cd-25-1761.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1761\/3738144\/cd-25-1761.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/4\/677\/3749589\/cd-25-1761.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/4\/677\/3749589\/cd-25-1761.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:14:52Z","timestamp":1775027692000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/4\/677\/775563\/Acquired-On-Target-Alterations-Drive-Clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-1761","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.31911043","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.8395765","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}